Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Abstract
Objective: To determine the effects of the N-methyl-D-aspartate (NMDA) antagonist amantadine on levodopa-associated dyskinesias and motor fluctuations in Parkinson's disease (PD).
Background: NMDA receptor blockade can ameliorate levodopa-induced dyskinesias in primates and PD patients. Amantadine, a well-tolerated and modestly effective antiparkinsonian agent, was recently found to possess NMDA antagonistic properties.
Methods: Eighteen patients with advanced PD participated in a double-blind, placebo-controlled, cross-over study. At the end of each 3-week treatment arm, parkinsonian and dyskinesia scores were obtained during a steady-state intravenous levodopa infusion. Motor fluctuations and dyskinesias were also documented with patient-kept diaries and Unified Parkinson's Disease Rating Scale (UPDRS) interviews.
Results: In the 14 patients completing this trial, amantadine reduced dyskinesia severity by 60% (p = 0.001) compared to placebo, without altering the antiparkinsonian effect of levodopa. Motor fluctuations occurring with patients' regular oral levodopa regimen also improved according to UPDRS and patient-kept diaries.
Conclusions: These findings suggest that amantadine given as adjuvant to levodopa can markedly improve motor response complications and support the view that hyperfunction of NMDA receptors contributes to the pathogenesis of levodopa-associated motor complications.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-372.
2.
Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
3.
Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
4.
Papa SM, Chase TN. Levodopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
5.
Verhagen Metman L, Blanchet PJ, Mouradian MM, Chase TN. Dextromethorphan and levodopa combination therapy in parkinsonian patients with response fluctuations. Mov Disord 1996;11:184. Abstract.
6.
Blanchet PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
7.
Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991;206:297-300.
8.
Kornhuber J, Quack G, Danysz W, et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;34:713-721.
9.
Kurlan R, Rothfield AB, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 1988;38:418-421.
10.
Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J Neural Transm Park Dis Dement Sect 1994;7:155-166.
11.
Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, ed. Statistical methods for rates and proportions. New York: Wiley and Sons, 1981:212-236.
12.
Rajput AH, Uitti RJ, Lang AE, Rajput AH. Amantadine ameliorates levodopa induced dyskinesia. Neurology 1997;48:328. Abstract.
13.
Adler C, Stern MB, Hurtig HI. Amantadine in advanced Parkinson's disease: good use of an old drug. J Neurol 1997;244:336-337.
14.
Freudenreich O, McEvoy JP. Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics. J Clin Psychiatry 1995;56:173. Letter.
15.
Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind cross-over, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167-170.
16.
Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987;10:522-526.
17.
Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971;174:408-410.
18.
Bailey EV, Stone TW. The mechanism of action of amantadine in parkinsonism: a review. Arch Int Pharmacodyn Ther 1975;216:246-262.
19.
Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl 1995;46:97-105.
20.
Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976;264:76-79.
21.
Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord 1993;8:512-514.
22.
Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994;43:91-104.
23.
Kornhuber J, Schoppmeyer K, Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in postmortem human frontal cortex. Neurosci Lett 1993;163:129-131.
24.
Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996;58:721-734.
Information & Authors
Information
Published In
Copyright
© 1998.
Publication History
Published online: May 1, 1998
Published in print: May 1998
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review, Medicina, 59, 11, (1991), (2023).https://doi.org/10.3390/medicina59111991
- Sleep Dysfunction in Huntington’s Disease: Impacts of Current Medications and Prospects for Treatment, Journal of Huntington's Disease, 12, 2, (149-161), (2023).https://doi.org/10.3233/JHD-230567
- Nitrenium ions as new versatile reagents for electrophilic amination, Chemical Science, 14, 43, (12034-12040), (2023).https://doi.org/10.1039/D3SC04268E
- Drug treatment of Parkinson's disease, Dialogues in Clinical Neuroscience, 6, 3, (315-322), (2022).https://doi.org/10.31887/DCNS.2004.6.3/akorczyn
- Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic, Neurodegenerative Disease Management, 12, 4, (203-214), (2022).https://doi.org/10.2217/nmt-2021-0055
- GOCOVRI ® (amantadine) extended-release capsules in Parkinson's disease , Neurodegenerative Disease Management, 12, 1, (15-28), (2022).https://doi.org/10.2217/nmt-2021-0028
- Guidelines for Parkinson’s disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms, Arquivos de Neuro-Psiquiatria, 80, 3, (316-329), (2022).https://doi.org/10.1590/0004-282x-anp-2021-0219
- Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection, Pharmacological Reviews, 73, 4, (1204-1268), (2022).https://doi.org/10.1124/pharmrev.120.000189
- An Improved Procedure for the Synthesis of Amantadine Hydrochloride, Organic Preparations and Procedures International, 54, 3, (236-241), (2022).https://doi.org/10.1080/00304948.2022.2027202
- Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease, npj Parkinson's Disease, 8, 1, (2022).https://doi.org/10.1038/s41531-022-00291-1
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.